Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Cytotherapy ; 25(6 Supplement):E6-E7, 2023.
Artigo em Inglês | EMBASE | ID: covidwho-20238652

RESUMO

Background & Aim: The long-term effects of human mesenchymal stem cell (MSC) treatment on COVID-19 patients have not been fully characterized. The aim of this study was to evaluate the safety and efficacy of a MSC treatment administered to severe COVID-19 patients enrolled in a randomized, double-blind, placebo-controlled clinical trial (NCT 04288102). Methods, Results & Conclusion(s): A total of 100 patients experiencing severe COVID-19 received either MSC treatment (n = 65, 4x107 cells per infusion) or a placebo (n = 35) combined with standard of care on days 0, 3, and 6. Patients were subsequently evaluated 18 and 24 months after treatment to evaluate the long-term safety and efficacy of the MSC treatment. The outcomes measured included: 6-minute walking distance (6-MWD), lung imaging, quality of life according to the Short Form 36 questionnaire, COVID-19-related symptoms, titers of SARS-CoV-2 neutralizing antibodies, MSC-related adverse events (AEs), and tumor markers. Two years after treatment, a marginally smaller proportion of patients had a 6-MWD below the lower limit of the normal range in the MSC group than in the placebo group (OR = 0.19, 95% CI: 0.04-0.80, Fisher's exact test, p = 0.015). On the SF-36 questionnaire, a marginally higher general health score was received by the MSC group at month 18 compared with the placebo group (50.00 vs. 35.00;95% CI: 0.00-20.00, Wilcoxon rank sum test, p = 0.016). In contrast, there were no differences in the total severity score of lung imaging or the titer of neutralizing antibodies between the two groups. Meanwhile, there were no MSC-related AEs reported at the 18- or 24-month follow-ups. The serum levels of most of the tumor markers examined remained within normal ranges and were similar between the MSC and placebo groups. Long-term safety was observed for the COVID-19 patients who received MSC treatment. Yet few sustained efficacy of MSC treatment was observed at the end of the 2-year follow-up period. Funding(s): The National Key Research and Development Program of China (2022YFA1105604, 2020YFC0860900), the specific research fund of The Innovation Platform for Academicians of Hainan Province (YSPTZX202216) and the Fund of National Clinical Center for Infectious Diseases, PLA General Hospital (NCRCID202105,413FZT6). [Figure presented]Copyright © 2023 International Society for Cell & Gene Therapy

2.
Post-COVID Economic Revival, Volume II: Sectors, Institutions, and Policy ; 2:271-283, 2022.
Artigo em Inglês | Scopus | ID: covidwho-2303661

RESUMO

This chapter, "Government Protection of Both Parties in the Operation of the Post-Epidemic Labor Market in China”, considers the situation with regulation of the labor market in China at the COVID and post-COVID period. In the post-epidemic period, when the epidemic prevention and control initially achieved results, China, as the first country to discover and report COVID-19 and the most successful country in epidemic prevention and control, implemented government protection policies for both sides in the labor market in terms of stabilizing employment, which achieved remarkable results and served as a model for other countries. Generally, the government protection policies of the Chinese government for both enterprises and labors include the following aspects. First, monetary, fiscal, and employment policies work together to stabilize employment, strengthen protection for both sides, and ensure the sound operation of the labor market. Second, the forms of employment are standardized and diversified in accordance with the law to effectively protect the legitimate rights and interests of labors and give enterprises greater flexibility and convenience in employment. Third, special assistance is offered to enterprises in difficulty, key employment groups, and the unemployed. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

3.
Chinese General Practice ; 26(5):607-620, 2023.
Artigo em Inglês | Scopus | ID: covidwho-2246738

RESUMO

Background The worldwide COVID-19 pandemic has turned into a global catastrophic public health crisis,and the conclusion about the risk factors of hospital death in COVID-19 patients is not uniform. Objective To explore risk factors of in-hospital death in patients with COVID-19 by a meta-analysis. Methods Case-control studies about risk factors of in-hospital death in COVID-19 patients were searched from databases of the Cochrane Library,ScienceDirect,PubMed,Medline,Wanfang Data,CNKI and CQVIP from inception to October 1,2021. Literature screening,data extraction and methodological quality assessment were conducted. Meta-analysis was performed using Stata 15.1. Meta-regression was used to explore the potential sources of heterogeneity. Results Eighty studies were included which involving 405 157 cases〔349 923 were survivors(86.37%),and 55 234 deaths(13.63%)〕,that were rated as being of high quality by the Newcastle-Ottawa Scale. Meta-analysis showed that being male〔OR=1.49,95%CI(1.41,1.57),P<0.001),older age〔WMD=10.44,95%CI(9.79,11.09),P<0.001〕,dyspnoea〔OR=2.09,95%CI(1.80,2.43),P<0.001〕,fatigue〔OR=1.49,95%CI(1.31,1.69),P<0.001〕,obesity〔OR=1.46,95%CI(1.43,1.50),P<0.001〕,smoking〔OR=1.18,95%CI (1.14,1.23),P<0.001〕,stroke〔OR=2.26,95%CI(1.41,3.62),P<0.001〕,kidney disease〔OR=3.62,95%CI (3.26,4.03),P<0.001〕,cardiovascular disease〔OR=2.34,95%CI(2.21,2.47),P<0.001〕,hypertension〔OR=2.23,95%CI(2.10,2.37),P<0.001〕,diabetes〔OR=1.84,95%CI(1.74,1.94),P<0.001〕,cancer〔OR=1.86,95%CI (1.69,2.05),P<0.001〕,pulmonary disease〔OR=2.38,95%CI(2.19,2.58),P<0.001〕,liver disease〔OR=1.65,95%CI(1.36,2.01),P<0.001〕,elevated levels of white blood cell count〔WMD=2.03,95%CI(1.74,2.32),P<0.001〕,neutrophil count〔WMD=1.77,95%CI(1.49,2.05),P<0.001〕,total bilirubin〔WMD=3.19,95%CI(1.96,4.42),P<0.001〕,aspartate transaminase〔WMD=13.02,95%CI(11.70,14.34),P<0.001〕,alanine transaminase 〔WMD=2.76,95%CI(1.68,3.85),P<0.001〕,lactate dehydrogenase〔WMD=166.91,95%CI(150.17,183.64),P<0.001〕,blood urea nitrogen〔WMD=3.11,95%CI(2.61,3.60),P<0.001〕,serum creatinine〔WMD=22.06,95%CI (19.41,24.72),P<0.001〕,C-reactive protein〔WMD=76.45,95%CI (71.33,81.56),P<0.001〕,interleukin-6 〔WMD=28.21,95%CI(14.98,41.44),P<0.001〕,and erythrocyte sedimentation rate〔WMD=8.48,95%CI(5.79,11.17),P<0.001〕were associated with increased risk of in-hospital death for patients with COVID-19,while myalgia〔OR=0.73,95%CI(0.62,0.85),P<0.001〕,cough〔OR=0.87,95%CI(0.78,0.97),P=0.013〕,vomiting〔OR=0.73,95%CI (0.54,0.98),P=0.030〕,diarrhoea〔OR=0.79,95%CI(0.69,0.92),P=0.001〕,headache〔OR=0.55,95%CI(0.45,0.68),P<0.001〕,asthma〔OR=0.73,95%CI(0.69,0.78),P<0.001〕,low body mass index〔WMD=-0.58,95%CI (-1.10,-0.06),P=0.029〕,decreased lymphocyte count〔WMD=-0.36,95%CI(-0.39,-0.32),P<0.001〕,decreased platelet count 〔WMD=-38.26,95%CI(-44.37,-32.15),P<0.001〕,increased D-dimer〔WMD=0.79,95%CI(0.63,0.95),P<0.001〕,longer prothrombin time〔WMD=0.78,95%CI(0.61,0.94),P<0.001〕,lower albumin〔WMD =-1.88,95%CI(-2.35,-1.40),P<0.001〕,increased procalcitonin〔WMD=0.27,95%CI(0.24,0.31),P<0.001〕,and increased cardiac troponin〔WMD=0.04,95%CI(0.03,0.04),P<0.001〕were associated with decreased risk of in-hospital death due to COVID-19. According to the meta-regression result,the heterogeneity in gender,renal disease,cardiovascular diseases,asthma,white blood cell count,neutrophil count,platelet count,hemoglobin,and urea nitrogen differed siangificnatly by country(P<0.05). Conclusion The risk of in-hospital death due to COVID-19 may be increased by 25 factors(including being male,older age,dyspnoea,fatigue,obesity,smoking,stroke,kidney disease,cardiovascular disease,hypertension,diabetes,cancer,pulmonary disease,liver disease,elevated levels of white blood cells,neutrophil count,total bilirubin,aspartate transaminase,alanine transaminase,lactate dehydrogenase,blood urea nitrogen,serum creatinine,C-reactive protein,interleukin-6,and erythrocyte sedimentation rate),and may be decreased by 13 factors(including myalgia,cough,vomiting,diarrhoea,headache,asthma,low body mass index,decreased lymphocyte count and platelet count,increased D-dimer,longer prothrombin time,lower albumin,increased procalcitonin and cardiac troponin). The conclusion drawn from this study needs to be further confirmed by high-quality,multicenter,large-sample,real-world studies. © 2023 Chinese General Practice. All rights reserved.

4.
International Journal of Electrical Power & Energy Systems ; 147, 2023.
Artigo em Inglês | Web of Science | ID: covidwho-2237559

RESUMO

The spread of the global COVID-19 epidemic has resulted in significant shifts in electricity consumption compared to regular days. It is unknown if standard single-task, single-indicator load forecasting algorithms can accurately reflect COVID-19 load patterns. Power practitioners urgently want a simple, efficient, and accurate solution for anticipating reliable load. In this paper, we first propose a unique collaborative TCN-LSTM-MTL short-term load forecasting model based on mobility data, temporal convolutional networks, and multi-task learning. The addition of the parameter sharing layers and the structure with residual convolution improves the data input diversity of the forecasting model and enables the model to obtain a wider time series receptive field. Then, to demonstrate the usefulness of the mobility optimized TCN-LSTM-MTL, tests were conducted in three levels and twelve base regions using 19 different benchmark models. It is capable of controlling predicting mistakes to within 1 % in the majority of tasks. Finally, to rigorously explain the model, the Shapley additive explanations (SHAP) visual model interpretation technology based on game theory is introduced. It examines the TCN-LSTM-MTL model's internal mechanism at various time periods and establishes the validity of the mobility indicators as well as the asynchronous relationship between indicator significance and real contribution.

5.
Chinese General Practice ; 26(5):607-620, 2023.
Artigo em Chinês | Scopus | ID: covidwho-2237526

RESUMO

Background The worldwide COVID-19 pandemic has turned into a global catastrophic public health crisis,and the conclusion about the risk factors of hospital death in COVID-19 patients is not uniform. Objective To explore risk factors of in-hospital death in patients with COVID-19 by a meta-analysis. Methods Case-control studies about risk factors of in-hospital death in COVID-19 patients were searched from databases of the Cochrane Library,ScienceDirect,PubMed,Medline,Wanfang Data,CNKI and CQVIP from inception to October 1,2021. Literature screening,data extraction and methodological quality assessment were conducted. Meta-analysis was performed using Stata 15.1. Meta-regression was used to explore the potential sources of heterogeneity. Results Eighty studies were included which involving 405 157 cases〔349 923 were survivors(86.37%),and 55 234 deaths(13.63%)〕,that were rated as being of high quality by the Newcastle-Ottawa Scale. Meta-analysis showed that being male〔OR=1.49,95%CI(1.41,1.57),P<0.001),older age〔WMD=10.44,95%CI(9.79,11.09),P<0.001〕,dyspnoea〔OR=2.09,95%CI(1.80,2.43),P<0.001〕,fatigue〔OR=1.49,95%CI(1.31,1.69),P<0.001〕,obesity〔OR=1.46,95%CI(1.43,1.50),P<0.001〕,smoking〔OR=1.18,95%CI (1.14,1.23),P<0.001〕,stroke〔OR=2.26,95%CI(1.41,3.62),P<0.001〕,kidney disease〔OR=3.62,95%CI (3.26,4.03),P<0.001〕,cardiovascular disease〔OR=2.34,95%CI(2.21,2.47),P<0.001〕,hypertension〔OR=2.23,95%CI(2.10,2.37),P<0.001〕,diabetes〔OR=1.84,95%CI(1.74,1.94),P<0.001〕,cancer〔OR=1.86,95%CI (1.69,2.05),P<0.001〕,pulmonary disease〔OR=2.38,95%CI(2.19,2.58),P<0.001〕,liver disease〔OR=1.65,95%CI(1.36,2.01),P<0.001〕,elevated levels of white blood cell count〔WMD=2.03,95%CI(1.74,2.32),P<0.001〕,neutrophil count〔WMD=1.77,95%CI(1.49,2.05),P<0.001〕,total bilirubin〔WMD=3.19,95%CI(1.96,4.42),P<0.001〕,aspartate transaminase〔WMD=13.02,95%CI(11.70,14.34),P<0.001〕,alanine transaminase 〔WMD=2.76,95%CI(1.68,3.85),P<0.001〕,lactate dehydrogenase〔WMD=166.91,95%CI(150.17,183.64),P<0.001〕,blood urea nitrogen〔WMD=3.11,95%CI(2.61,3.60),P<0.001〕,serum creatinine〔WMD=22.06,95%CI (19.41,24.72),P<0.001〕,C-reactive protein〔WMD=76.45,95%CI (71.33,81.56),P<0.001〕,interleukin-6 〔WMD=28.21,95%CI(14.98,41.44),P<0.001〕,and erythrocyte sedimentation rate〔WMD=8.48,95%CI(5.79,11.17),P<0.001〕were associated with increased risk of in-hospital death for patients with COVID-19,while myalgia〔OR=0.73,95%CI(0.62,0.85),P<0.001〕,cough〔OR=0.87,95%CI(0.78,0.97),P=0.013〕,vomiting〔OR=0.73,95%CI (0.54,0.98),P=0.030〕,diarrhoea〔OR=0.79,95%CI(0.69,0.92),P=0.001〕,headache〔OR=0.55,95%CI(0.45,0.68),P<0.001〕,asthma〔OR=0.73,95%CI(0.69,0.78),P<0.001〕,low body mass index〔WMD=-0.58,95%CI (-1.10,-0.06),P=0.029〕,decreased lymphocyte count〔WMD=-0.36,95%CI(-0.39,-0.32),P<0.001〕,decreased platelet count 〔WMD=-38.26,95%CI(-44.37,-32.15),P<0.001〕,increased D-dimer〔WMD=0.79,95%CI(0.63,0.95),P<0.001〕,longer prothrombin time〔WMD=0.78,95%CI(0.61,0.94),P<0.001〕,lower albumin〔WMD =-1.88,95%CI(-2.35,-1.40),P<0.001〕,increased procalcitonin〔WMD=0.27,95%CI(0.24,0.31),P<0.001〕,and increased cardiac troponin〔WMD=0.04,95%CI(0.03,0.04),P<0.001〕were associated with decreased risk of in-hospital death due to COVID-19. According to the meta-regression result,the heterogeneity in gender,renal disease,cardiovascular diseases,asthma,white blood cell count,neutrophil count,platelet count,hemoglobin,and urea nitrogen differed siangificnatly by country(P<0.05). Conclusion The risk of in-hospital death due to COVID-19 may be increased by 25 factors(including being male,older age,dyspnoea,fatigue,obesity,smoking,stroke,kidney disease,cardiovascular disease,hypertension,diabetes,cancer,pulmonary disease,liver disease,elevated levels of white blood cells,neutrophil count,total bilirubin,aspartate transaminase,alanine transaminase,lactate dehydrogenase,blood urea nitrogen,serum creatinine,C-reactive protein,interleukin-6,and erythrocyte sedimentation rate),and may be decreased by 13 factors(including myalgia,cough,vomiting,diarrhoea,headache,asthma,low body mass index,decreased lymphocyte count and platelet count,increased D-dimer,longer prothrombin time,lower albumin,increased procalcitonin and cardiac troponin). The conclusion drawn from this study needs to be further confirmed by high-quality,multicenter,large-sample,real-world studies. © 2023 Chinese General Practice. All rights reserved.

6.
Infectious Diseases and Immunity ; 1(1):52-58, 2021.
Artigo em Inglês | Scopus | ID: covidwho-2212932

RESUMO

Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2 infection (causing coronavirus disease 2019 [COVID-19]) are serious diseases. To date, no effective post-exposure prophylaxis, prevention, or therapeutic agents are recommended as effective for these diseases. Convalescent plasma (CP), donated by individuals with established humoral immunity to the virus after recovering from coronavirus infection, has been successfully applied to treat several infectious diseases, including SARS, MERS, and COVID-19. Nonetheless, there are obstacles and challenges to using CP that should be taken into account. In this review, we summarize the evidence derived from clinical attempts to treat COVID-19 with CP, which represents a promising therapy for severe coronavirus infection. Furthermore, we outline the remaining challenges and general issues that should be considered when using CP treatment for therapeutic or prophylactic purposes. © 2021 The Chinese Medical Association, Published by Wolters Kluwer Health, Inc.

8.
Advanced Therapeutics ; 5(8), 2022.
Artigo em Inglês | EMBASE | ID: covidwho-2007088

RESUMO

Cancer gene therapy based on various gene delivery vectors has some potential but also has obvious disadvantages. In this study, a new M13 phage-based oncolytic virus is constructed that carried the RGD peptides to target tumor cells and the 3C gene of Seneca Valley virus (SVV) preceded by a eukaryotic initial transcriptional region (ITR) to transcribe an oncolytic protein to kill tumor cells. Recombinant virus particles of 1200 nm in length are obtained in large quantities by transfecting the recombinant M13 phage plasmid into the host BL2738 and are investigated in vitro in tumor cells and in vivo in tumor-bearing mice to evaluate their antitumor effect. The experiments using Hela cells confirm that the engineered M13 phage can target and enter Hela cells, and express the SVV 3C protein, resulting in apoptosis of target cells by upregulating the expression of caspase 3. Furthermore, the results of experiments in vivo also show that the recombinant phage significantly inhibits the enhanced tumor volume in nude mice compared to the control groups. The M13 phage may be engineered to fuse with a variety of oncolytic proteins to inhibit the growth of tumor cells in the future, providing a promising phage-based targeted oncolytic reagent.

9.
47th IEEE International Conference on Acoustics, Speech, and Signal Processing, ICASSP 2022 ; 2022-May:9012-9016, 2022.
Artigo em Inglês | Scopus | ID: covidwho-1891401

RESUMO

Traditional face-to-face subjective listening test has become a challenge due to the COVID-19 pandemic. We developed a remote assessment system with Tencent Meeting, a video conferencing application, to address this issue. This paper presents our work on evaluating the reliability of the remote assessment system. Two speech reception threshold (SRT) experiments were conducted to study the effects of noise suppression and maxima selection number on cochlear implant (CI) hearing. Both experiments were conducted locally and remotely, the correlations between the respective results were analyzed. Results showed that remote tests replicated the differences among testing conditions observed in local tests, but the absolute SRT values for individual conditions varied significantly between the two modes. The variations could be attributed to multiple reasons, such as online data transmission issues, audio playback devices, environmental conditions, and the training of participants. In conclusion, the relative variation of SRTs for CIs can be measured reliably, but the absolute SRT values should be carefully compared and explained according to objective and subjective experimental conditions. © 2022 IEEE

10.
Diabetes research and clinical practice ; 186:109368-109368, 2022.
Artigo em Inglês | EuropePMC | ID: covidwho-1876994
12.
2021 International Conference on Culture-Oriented Science and Technology, ICCST 2021 ; : 268-272, 2021.
Artigo em Inglês | Scopus | ID: covidwho-1672715

RESUMO

In recent years, novel coronavirus pneumonia has spread rapidly around the world due to its strong infectiousness, and the medical systems of related countries are facing huge challenges. As the most intuitive and effective supplementary diagnostic basis for the results of nucleic acid tests, medical imaging screening has gradually become more and more important in epidemic prevention and control. In this context, this paper develops a novel coronavirus pneumonia-auxiliary diagnostic system by using deep learning techniques. This system can help medical staffs to diagnose the condition through X-Ray images quickly. This system builds a sample dataset by collecting lung X-ray images from two datasets and uses a neural network for auxiliary diagnosis training, which achieves an accuracy rate of 98%. Furthermore, two interactive visual interfaces in the form of PC-side applet and Web page are supported in the system, which makes it much easier for medical personnel to operate the system. © 2021 IEEE.

13.
2021 IEEE International Conference on Artificial Intelligence and Computer Applications, ICAICA 2021 ; : 82-85, 2021.
Artigo em Inglês | Scopus | ID: covidwho-1405130

RESUMO

In the current serious COVID-19 epidemic environment, disinfection is a laborious and extremely risky task. To improve the disinfection efficiency and reduce the disinfection risky, in this paper, the intelligent robot collaborative disinfection problem is constructed as a Distributed constrained optimization problem, in which each intelligent disinfection robot is modeled as an Agent and the constraint graph is constructed based on the actual application scenario to optimize the comprehensive benefits of energy consumption and machine wear of disinfection robots in the collaborative working process. The Proposed Distributed constrained optimization problem model is solved by the state-of-the-art algorithms DSA, MGM, Max-Sum and RM. Based on our extensive empirical evaluations, we experimentally show that the constructed Distributed constrained optimization problem model for intelligent robot collaborative disinfection can effectively plan the optimal collaborative robot patterns for identified disinfection scenarios as well as recommend the optimum parameters for each disinfection robot. © 2021 IEEE.

14.
Cogent Social Sciences ; 7(1):16, 2021.
Artigo em Inglês | Web of Science | ID: covidwho-1349734

RESUMO

Topic modeling, which uses machine learning algorithms to identify the emergence of topics, can help public health professionals monitor online public responses during health crises. This study used Latent Dirichlet Allocation algorithm to model the topics in Twitter messages (or "tweets") from the US during the COVID-19 pandemic from March 20th to August 9th, 2020. Topic sizes and sentiment were calculated as the pandemic evolved, for major topics about vaccination and mask-wearing as a nonpharmaceutical intervention measure. Despite the pandemic, positive sentiments were found among most topics. While users were found to react more often to positive sentiment about mask-wearing, negative content on vaccination was found more popular. Noticeable trends in topic sizes and sentiment were observed for various topics, which correlated in time with some key pandemic events and policy changes, implying their impacts on social media responses. By analyzing such trends and impacts, this research offers insights on health campaign message design and how to outreach the general public most effectively.

15.
World Journal of Traditional Chinese Medicine ; 7(2):258-264, 2021.
Artigo em Inglês | EMBASE | ID: covidwho-1270177

RESUMO

Background: The global outbreak of coronavirus disease 2019 (COVID-19) has brought disastrous consequences to public health and medical systems, whereas no approved medications are currently available. Benefits of traditional Chinese medicine (TCM) against COVID-19 have been observed, however, the underlying mechanistic actions remain unclarified. Due to high pathogenicity and infectivity of the new coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), the lack of access to SARS-CoV-2 and biosafety level 3 (P3) facilities has impeded scientific investigations of TCM against COVID-19. Though low-pathogenic coronavirus and pseudoviral systems have been applied to substitute SARS-CoV-2 in fundamental studies, both models cannot imitate virological and clinical features associated with SARS-CoV-2. The virus-like particle (VLP) is a virological model that is safe and could be performed without biosafety protections. Aims and Objectives: To construct VLP of SARS-CoV-2 containing structural proteins of authentic viruses and resembling the morphology, partial life cycle, and immunoreactions of natural virions, and to introduce VLP into Chinese medical research. Materials and Methods: Using mammalian expression system, we have currently constructed SARS-CoV-2 VLP containing four essential structural proteins. Results: Based on this model, we propose six aspects of research that could be carried out for TCM formulas in the fight against COVID-19. Conclusion: Application of the VLP model provides a safe methodology to strengthen the response systems of Chinese medicine in preventing and controlling newly identified infectious diseases and offers collaborative opportunities for interdisciplinary deciphering of molecular and biological basis of anti-viral TCM formulas. ©2021 World Journal of Traditional Chinese Medicine ;Published by Wolters Kluwer . Medknow.

16.
Chinese Journal of General Practitioners ; 20(5):533-539, 2021.
Artigo em Chinês | Scopus | ID: covidwho-1239026

RESUMO

Objective: To analyze Traditional Chinese Medicine(TCM) prescriptions in COVID-19 patients in Shanghai area. Methods: Two hundred and forty patients were enrolled in the study, including 19 mild cases, 199 moderate cases, 16 severe case and 6 critical cases. The COVID-19 formula in Shanghai area was extracted and input in TCM Inheritance platform. Data association method such as software association rules,improved mutual information method,complex system entropy clustering,unsupervised entropy hierarchical clustering were used to analyze the frequency,herb flavor and meridian, combination rule and core combination of different types of Chinese herbs in the treatment of COVID-19 in Shanghai area. Results: According to the frequency analysis of 240 prescriptions of Chinese medicine,194 herbs were found. The COVID-19 formula herbs were all "cold", the frequency of use in mild, moderate, severe and critical cases was [46.02%(104/226), 46.31%(1 230/2 656), 37.06%(146/394), 39.24%(31/79)]. The flavor was mainly "bitter" and the frequency of use in 4 types of disease were [36.53%(122/332), 37.33%(1 445/3 857), 35.96%(205/564), 33.62%(39/113)]. Scutellaria was the most frequently used TCM of "bitter and cold". The drugs used were mainly lung,stomach and spleen meridians. By comparing the formulas between mild and moderate cases,herb combinations with the highest frequency were all "scutellaria glycyrrhiza" and "tangerine glycyrrhiza". The formulas for 19 mild cases were collected,and 197 drug combinations were counted, and 125 Chinese medicine association rules,including 13 Chinese herbs. The formulas were extracted in 199 moderate cases of COVID-19, a total of 92 drug combinations and 38 Chinese medicine association rules were collected,including 19 Chinese herbs. In 16 severe cases, a total of 62 drug combination models and 46 Chinese medicine association rules were collected,including 17 Chinese herbs. For the 6 critical cases,80 Chinese medicine prescriptions were combined,and 10 Chinese medicine association rules, including 12 Chinese herbs. Conclusions: The herbal prescriptions of COVID-19 in Shanghai are characterized by clearing away heat and resolving dampness. By analyzing prescription rules with complex system entropy clustering, association compatibility ideas of different types of traditional Chinese medicine are found to be different among four types of COVID-19 cases. Analyzing the connection rules in formulas, by using the theory of TCM and pharmacology of traditional Chinese medical formula in different COVID-19 patients may be helpful for general practitioners. © 2021 Chinese Medical Association

17.
Iranian Journal of Public Health ; 49(11):2022-2031, 2020.
Artigo em Inglês | Scopus | ID: covidwho-919961

RESUMO

Background: COVID-19 is a public health emergency of international concern. Its incidence rates and mortality are very high;however, so far, an effective drug treatment remains unknown. Based on the role of convalescent plasma therapy in previously identified viral pneumonias, patients with severe COVID-19 have been given this therapy. This systematic review and meta-analysis aimed to summarize the clinical evidence regarding the efficacy and safety of convalescent plasma therapy in the treatment of severe COVID-19. Methods: PubMed, Embase, Ovid, China Knowledge Network, China Biomedical, VIP Chinese Sci-tech Journal, Wanfang Database, and the International Clinical Trials Registry Platform were searched up to 21 June 2020, to identify clinical studies and registered trials on the use of convalescent plasma in the treatment of critically ill patients with COVID-19. Stata 13.0 was used to perform Meta-analysis. All records were screened as per the protocol eligibility criteria. Results: Nineteen clinical reports regarding convalescent plasma in the treatment of severe COVID-19 were included. Through systematic analysis, convalescent plasma was found to yield some efficacy on severe COVID-19 and had almost no obvious adverse reactions. Conclusion: Convalescent plasma therapy seems to yield some efficacy among patients with severe COVID-19 and almost no obvious adverse reactions were found. However, at present, the clinical evidence is insufficient, and there is an urgent need for support from high-quality clinical trial data. © 2020, Iranian Journal of Public Health. All rights reserved.

18.
J Endocrinol Invest ; 44(5): 1031-1040, 2021 May.
Artigo em Inglês | MEDLINE | ID: covidwho-898191

RESUMO

OBJECTIVE: COVID-19 is a new coronavirus infectious disease. We aimed to study the characteristics of thyroid hormone levels in patients with COVID-19 and to explore whether thyroid hormone predicts all-cause mortality of severely or critically ill patients. METHODS: The clinical data of 100 patients with COVID-19, who were admitted to Wuhan Tongji Hospital from February 8 to March 8, 2020, were analyzed in this retrospective study. The patients were followed up for 6-41 days. Patients were grouped into non-severe illness and severe or critical illness, which included survivors and non-survivors. Multivariate Cox proportional hazards analysis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality in association with continuous and the lower two quartiles of thyroid hormone concentrations in severely or critically ill patients. RESULTS: The means of free T3 (FT3) were 4.40, 3.73 and 2.76 pmol/L in non-severely ill patients, survivors and non-survivors, respectively. The lower (versus upper) two quartiles of FT3 was associated with all-cause mortality HR (95% CI) of 9.23 (2.01, 42.28). The HR (95% CI) for all-cause mortality in association with continuous FT3 concentration was 0.41 (0.21, 0.81). In the multivariate-adjusted models, free T4 (FT4), TSH and FT3/FT4 were not significantly related to all-cause mortality. Patients with FT3 less than 3.10 pmol/L had increased all-cause mortality. CONCLUSION: FT3 concentration was significantly lower in patients with severe COVID-19 than in non-severely ill patients. Reduced FT3 independently predicted all-cause mortality of patients with severe COVID-19.


Assuntos
COVID-19/sangue , Hormônios Tireóideos/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/mortalidade , Causas de Morte , China/epidemiologia , Comorbidade , Estado Terminal/mortalidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Análise de Sobrevida , Testes de Função Tireóidea , Tri-Iodotironina/sangue
19.
Chinese Journal of Perinatal Medicine ; 23(4):220-223, 2020.
Artigo em Chinês | Scopus | ID: covidwho-826082

RESUMO

We report a critically ill pregnant woman in the third trimester with severe pneumonia due to COVID-19 who presented to Xiaolan People's Hospital of Zhongshan in February 2020. The 32-year-old patient was admitted at 35+2 gestational weeks with a 4-day history of a sore throat and a fever for three hours. The patient had been to Xiaogan City, Hubei Province, and the symptoms occurred during a period of self-isolation after back home. The condition of the patient deteriorated rapidly, with left-sided chest and back pain, shortness of breath, dizziness, progressing to respiratory failure and septic shock 7 hours after her admission. In view of her critical condition and a history of two previous cesarean sections, an emergency cesarean section was performed. Blood gas analysis of the mother before the operation suggested respiratory failure, respiratory acidosis, and metabolic acidosis. During the operation, a baby boy was born. The Apgar score of the boy, birth weight of 2 700 g, was one at 1, 5, and 10 minutes despite the resuscitation efforts. The neonate died after withdrawing treatment. The patient was treated with tracheal intubation ventilator and other supportive treatments after the operation. The result of the new coronavirus nucleic acid test, taken on admission, but which was reported after delivery, was positive. The patient was transferred to the designated hospital for further treatment and was recovering with the withdrawal of extracorporeal membrane oxygenation and ventilation at 26 and 36 days after surgery, respectively. Copyright © 2020 by the Chinese Medical Association.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA